Skip to main content
SpringerLink
Log in

Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Plasma levels of free and sulfoconjugated 3,4-dihydroxyphenylethyleneglycol (DOPEG), the main deaminated metabolite of norepinephrine, were measured in a group of 45 hospitalized patients presenting a major depression and a group of 45 healthy subjects, matched for sex and age. Compared to healthy subjects, depressed patients had significantly lower plasma levels of free and sulfoconjugated DOPEG. The ratio of free over conjugated DOPEG was not statistically different in the two groups. The reduction of plasma DOPEG levels in the depressed patients did not appear to be related to the duration of drug-free period and was similar in males and females. There was no statistically significant correlation between plasma DOPEG levels and total score on the Hamilton Rating Scale for Depression. Finally, plasma DOPEG levels did not differ in unior bipolar patients. The present data provides further evidence for a reduced CNS noradrenergic transmission in major depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger V (1976) “Serotonin depression”: A biochemical subgroup within the affective disorders? Science 191:478–480

    Google Scholar 

  • Beckmann H, Goodwin FK (1975) Antidepressant response to triclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline. Arch Gen Psychiatry 32:17–21

    Google Scholar 

  • Beckmann H, Goodwin FK (1980) Urinary MHPG in subgroups of depressed patients and normal controls. Neuropsychobiology 6:91–100

    Google Scholar 

  • Berger PA, Faull KF, Kilkowski J, Anderson PJ, Kraemer H, Davis K, Barchas JD (1980) CSF monoamine metabolites in depression and schizophrenia. Am J Psychiatry 137:174–180

    Google Scholar 

  • Bunney WE Jr, Davis JM (1965) Norepinephrine in depressive reactions. Arch Gen Psychiatry 13:483–494

    Google Scholar 

  • Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA (1981) A specific laboratory test for the diagnosis of melancholia. Standardization, validation and clinical utility. Arch Gen Psychiatry 38:15–22

    Google Scholar 

  • Coppen A, Prange AJ, Whybrow PC, Hill C, Noguera R (1972) Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry 26:474–478

    Google Scholar 

  • Crawley JN, Hattox SE, Maas JW, Roth RH (1978) 3-Methoxy-4-hydroxyphenylethyleneglycol increase in plasma after stimulation of the nucleus locus coeruleus. Brain Res 141:380–384

    Google Scholar 

  • Dennis T, Scatton B (1982) A radioenzymatic technique for the measurement of free and conjugated 3,4-dihydroxyphenylethyleneglycol in brain tissue and biological fluids. J Neurosci Methods 6:369–382

    Google Scholar 

  • Domino EF, Dren AT, Giardina WJ (1978) Biochemical and neurotransmitter change in the aging brain. In: Lipton MA, Di Mascio A, Killam FK (eds) Psychopharmacology: A generation of progress, New York, Raven Press, pp 1507–1515

    Google Scholar 

  • Edwards DJ, Spiker DG, Neil JF, Kupfer DJ, Rizk M (1980) MHPG excretion in depression. Psychiatr Res 2:295–305

    Google Scholar 

  • Elsworth JD, Redmond DE Jr, Roth RH (1982) Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates. Brain Res 225:115–124

    Google Scholar 

  • Garver DL, Davis JM (1979) Biogenic amine hypotheses of affective disorders. Life Sci 24:383–394

    Google Scholar 

  • Goodwin FK, Post RM, Dunner DL, Gordon EK (1973) Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique. Am J Psychiatry 130:73–79

    Google Scholar 

  • Goodwin FK, Wirz-Justice A, Wehr TA (1982) Evidence that the pathophysiology of depression and the mechanism of action of antidepressant drugs both involve alterations in circadian rhythms. Adv Biochem Psychopharmacol 32:1–11

    Google Scholar 

  • Gorden EK, Oliver J (1971) 3-Methoxy-4-hydroxy phenylethylene glycol in human CSF. Clin Chim Acta 35:145–150

    Google Scholar 

  • Hamilton M (1967) The development of rating scale of depression. Brit J Soc Clin Psychol 6:278–296

    Google Scholar 

  • Hollister LE, Davis KL, Overall JE, Anderson T (1978) Excretion of MHPG in normal subjects. Implications for biological classification of affective disorders. Arch Gen Psychiat 35:1410–1415

    Google Scholar 

  • Hollister LE, Davis KL, Berger PA (1980) Subtypes of depression based on excretion of MHPG and response to nortriptyline. Arch Gen Psychiatry 37:1107–1110

    Google Scholar 

  • Huff JW, Reigle TG (1980) Effects of morphine and other centrally actings drugs on 3,4-dihydroxyphenylethyleneglycol (DOPEGSO4) in rat brain. Life Sci 27:1483–1488

    Google Scholar 

  • Koester G, Breuer H, Schneider HT (1982) Effect of 2 substituted estrogens in vivo on the metabolism of noradrenaline in the rat brain. Acta Endocrinol 99:1–8

    Google Scholar 

  • Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ (1982) Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol Science 219:73–75

    Google Scholar 

  • Koslow SH, Maas JW, Bowden CL, Davis JM, Hanin I, Javaid J (1983) CSF and urinary biogenic amines and metabolites in depression and mania. Arch Gen Psychiatry 40:999–1010

    Google Scholar 

  • Loo H, Zarifian E (1982) Abord critique des facteurs biochimiques au cours des syndromes dépressifs et prescription d'antidépresseurs. Ann Médicopsychol 140:240–250

    Google Scholar 

  • Loo H, Scatton B, Le Fur G, Gay C, Benkelfat C, Susini-Deluca H, Poirier MF, Olié JP, Askienazy S (1984) Place of indalpine in psychiatric treatment. Adv Biol Psychiat 14:76–85

    Google Scholar 

  • Maas JW (1975) Biogenic amines and depression. Arch Gen Psychiatry 32:1357–1364

    Google Scholar 

  • Maas JW (1978) Clinical and biochemical heterogeneity of depressive disorders. Ann Int Med 88:556–563

    Google Scholar 

  • Maas JW, Fawcett J, Dekirmenjian H (1968) 3-Methoxy-4-hydroxyphenylglycol (MHPG) excretion in depressive states: a pilot study. Arch Gen Psychiatry 19:129–134

    Google Scholar 

  • Pickar D, Sweeney DR, Maas JW, Heninger GR (1978) Primary affective disorder, clinical state change, and MHPG excretion: A longitudinal study. Arch Gen Psychiatry 35:1378–1383

    Google Scholar 

  • Post RM, Gordon EK, Goodwin FK, Bunney WE (1973) Central norepinephrine metabolism in affective illness: MHPG in the CSF. Science 179:1002–1003

    Google Scholar 

  • Ramon De La Fuente J, Rosenbaum AH (1978) Clinical and neuroendocrine correlates of elevated platelet M.A.O. activity. Am J Psychiatry 135:994

    Google Scholar 

  • Robinson DS, Johnson GA, Nies A, Corcella J, Cooper TB, Albright D, Howard D (1983) Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J Clin Psychopharmacol 3:282–287

    Google Scholar 

  • Rosenbaum AM, Schatzberg AF, Maruta T, Orsulak PJ, Cole JO, Grab EL, Schildkraut JJ (1980) MHPG as a predictor of antidepressant response to imipramine and maprotiline. Am J Psychiatry 137:1090–1092

    Google Scholar 

  • Sachar EJ (1975) Neuroendocrine dysfunction in depressive illness. Ann Rev Med 27:389–396

    Google Scholar 

  • Scatton B (1982) Brain 3,4-dihydroxyphenylethyleneglycol levels are dependent on central noradrenergic neuron activity. Life Sci 31:495–504

    Google Scholar 

  • Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509–522

    Google Scholar 

  • Schildkraut JJ (1973) Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: preliminary findings. Am J Psychiatry 130:695–698

    Google Scholar 

  • Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, La Brie RA (1978) Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depression. Arch Gen Psychiatry 35:1427–1433

    Google Scholar 

  • Schlesser MA, Winokur G, Sherman BM (1980) Hypothalamicpituitary-adrenal axis activity in depressive illness. Its relationship to classification. Arch Gen Psychiatry 37:737–743

    Google Scholar 

  • Shaw DM, O'Keeffe R, MacSweeney DA, Brooksbank BW, Noguera R, Coppen A (1973) 3-Methoxy-4-hydroxyphenylglycol in depression. Psychol Med 3:333–336

    Google Scholar 

  • Subrahmanyam S (1975) Role of biogenic amines in certain pathological conditions. Brain Res 87:355–362

    Google Scholar 

  • Van Praag HM (1977) Significance of biochemical parameters in the diagnosis, treatment and prevention of depressive disorders. Biol Psychiatry 12:101–131

    Google Scholar 

  • Van Praag HM, Korf J, Schut D (1973) Cerebral monoamines and depression: an investigation with the probenecid technique. Arch Gen Psychiatry 28:827–831

    Google Scholar 

  • Vestergaard P, Sorensen T, Hoppe E, Rafaelsen OJ, Yates CM, Nicolaou N (1978) Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatr Scand 58:88–96

    Google Scholar 

  • Wehr TA, Wirz-Justice A (1982) Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 15:31–39

    Google Scholar 

  • Wilk S, Shopsin B, Gershon S, Suhl M (1972) Cerebrospinal fluid levels of MHPG in affective disorders. Nature 235:440–441

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratories d'Etudes et de Recherches Synthélabo, Biochemical Pharmacology Group, 31 avenue Paul Vaillant Couturier, F-92220, Bagneux, France

    Bernard Scatton & Trevor Dennis

  2. Hôpital Sainte Anne, 1 rue Cabanis, F-75014, Paris, France

    Henri Loo, Chawki Benkelfat, Christian Gay & Marie-France Poirier-Littre

Authors
  1. Bernard Scatton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henri Loo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Trevor Dennis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chawki Benkelfat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Gay
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marie-France Poirier-Littre
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scatton, B., Loo, H., Dennis, T. et al. Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression. Psychopharmacologia 88, 220–225 (1986). https://doi.org/10.1007/BF00652244

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00652244

Key words

Search

Navigation